Definitive chemoradiotherapy in patients with squamous cell cancers of the head and neck - results from an unselected cohort of the clinical cooperation group "Personalized Radiotherapy in Head and Neck Cancer".
Chemoradiation
Defintive
HNSCC
HPV
Head and neck cancer
Primary
Radiotherapy
Journal
Radiation oncology (London, England)
ISSN: 1748-717X
Titre abrégé: Radiat Oncol
Pays: England
ID NLM: 101265111
Informations de publication
Date de publication:
06 Jan 2020
06 Jan 2020
Historique:
received:
11
09
2019
accepted:
23
12
2019
entrez:
8
1
2020
pubmed:
8
1
2020
medline:
21
8
2020
Statut:
epublish
Résumé
Definitive chemoradiotherapy (dCRT) is a standard treatment for patients with locally advanced head and neck cancer. There is a clinical need for a stratification of this prognostically heterogeneous group of tumors in order to optimize treatment of individual patients. We retrospectively reviewed all patients with head and neck squamous cell carcinoma (HNSCC) of the oral cavity, oropharynx, hypopharynx, or larynx, treated with dCRT from 09/2008 until 03/2016 at the Department of Radiation Oncology, LMU Munich. Here we report the clinical results of the cohort which represent the basis for biomarker discovery and molecular genetic research within the framework of a clinical cooperation group. Patient data were collected and analyzed for outcome and treatment failures with regard to previously described and established risk factors. We identified 184 patients with a median follow-up of 65 months and a median age of 64 years. Patients received dCRT with a median dose of 70 Gy and simultaneous chemotherapy in 90.2% of cases, mostly mitomycin C / 5-FU in concordance with the ARO 95-06 trial. The actuarial 3-year overall survival (OS), local, locoregional and distant failure rates were 42.7, 29.8, 34.0 and 23.4%, respectively. Human papillomavirus-associated oropharynx cancer (HPVOPC) and smaller gross tumor volume were associated with significantly improved locoregional tumor control rate, disease-free survival (DFS) and OS in multivariate analysis. Additionally, lower hemoglobin levels were significantly associated with impaired DFS und OS in univariate analysis. The extent of lymph node involvement was associated with distant failure, DFS and OS. Moreover, 92 patients (50%) of our cohort have been treated in concordance with the ARO 95-06 study, corroborating the results of this study. Our cohort is a large unselected monocentric cohort of HNSCC patients treated with dCRT. Tumor control rates and survival rates compare favorably with the results of previously published reports. The clinical data, together with the available tumor samples from biopsies, will allow translational research based on molecular genetic analyses.
Sections du résumé
BACKGROUND
BACKGROUND
Definitive chemoradiotherapy (dCRT) is a standard treatment for patients with locally advanced head and neck cancer. There is a clinical need for a stratification of this prognostically heterogeneous group of tumors in order to optimize treatment of individual patients. We retrospectively reviewed all patients with head and neck squamous cell carcinoma (HNSCC) of the oral cavity, oropharynx, hypopharynx, or larynx, treated with dCRT from 09/2008 until 03/2016 at the Department of Radiation Oncology, LMU Munich. Here we report the clinical results of the cohort which represent the basis for biomarker discovery and molecular genetic research within the framework of a clinical cooperation group.
METHODS
METHODS
Patient data were collected and analyzed for outcome and treatment failures with regard to previously described and established risk factors.
RESULTS
RESULTS
We identified 184 patients with a median follow-up of 65 months and a median age of 64 years. Patients received dCRT with a median dose of 70 Gy and simultaneous chemotherapy in 90.2% of cases, mostly mitomycin C / 5-FU in concordance with the ARO 95-06 trial. The actuarial 3-year overall survival (OS), local, locoregional and distant failure rates were 42.7, 29.8, 34.0 and 23.4%, respectively. Human papillomavirus-associated oropharynx cancer (HPVOPC) and smaller gross tumor volume were associated with significantly improved locoregional tumor control rate, disease-free survival (DFS) and OS in multivariate analysis. Additionally, lower hemoglobin levels were significantly associated with impaired DFS und OS in univariate analysis. The extent of lymph node involvement was associated with distant failure, DFS and OS. Moreover, 92 patients (50%) of our cohort have been treated in concordance with the ARO 95-06 study, corroborating the results of this study.
CONCLUSION
CONCLUSIONS
Our cohort is a large unselected monocentric cohort of HNSCC patients treated with dCRT. Tumor control rates and survival rates compare favorably with the results of previously published reports. The clinical data, together with the available tumor samples from biopsies, will allow translational research based on molecular genetic analyses.
Identifiants
pubmed: 31906998
doi: 10.1186/s13014-019-1452-4
pii: 10.1186/s13014-019-1452-4
pmc: PMC6945615
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
7Références
Mol Oncol. 2018 Dec;12(12):2085-2101
pubmed: 30259648
Eur Arch Otorhinolaryngol. 2016 Dec;273(12):4595-4600
pubmed: 27372745
Laryngoscope. 2015 Jan;125(1):86-91
pubmed: 25124183
Strahlenther Onkol. 2018 Aug;194(8):759-770
pubmed: 29774396
Radiother Oncol. 2016 Feb;118(2):238-43
pubmed: 26589131
Radiother Oncol. 2018 Jan;126(1):107-115
pubmed: 29100700
Radiother Oncol. 2009 Jul;92(1):4-14
pubmed: 19446902
Lancet Oncol. 2013 Jul;14(8):697-710
pubmed: 23746666
J Clin Oncol. 2017 Feb 10;35(5):490-497
pubmed: 28029303
Strahlenther Onkol. 2016 Aug;192(8):552-60
pubmed: 27323753
PLoS One. 2018 Oct 22;13(10):e0205712
pubmed: 30347001
Ann Oncol. 2019 Oct 1;30(10):1673
pubmed: 31168601
Lancet Oncol. 2012 Feb;13(2):145-53
pubmed: 22261362
Lancet. 2019 Jan 5;393(10166):40-50
pubmed: 30449625
Radiat Oncol. 2018 Oct 4;13(1):195
pubmed: 30286777
Nutrition. 2017 Mar;35:114-118
pubmed: 28241978
Radiat Oncol. 2017 Jan 13;12(1):13
pubmed: 28086954
N Engl J Med. 2008 Sep 11;359(11):1116-27
pubmed: 18784101
Radiother Oncol. 2011 Jul;100(1):33-40
pubmed: 21684027
Laryngoscope. 2006 Nov;116(11):2067-70
pubmed: 17075409
Radiother Oncol. 2016 Dec;121(3):364-373
pubmed: 27913065
Int J Radiat Oncol Biol Phys. 2015 Apr 1;91(5):916-24
pubmed: 25670541
Radiat Oncol. 2015 Aug 25;10:181
pubmed: 26302761
Lancet Oncol. 2019 Oct;20(10):1349-1359
pubmed: 31416685
Curr Treat Options Oncol. 2017 Jul;18(7):40
pubmed: 28555375
Int J Cancer. 2019 Apr 15;144(8):1941-1953
pubmed: 30350310
Radiother Oncol. 2017 Jun;123(3):424-430
pubmed: 28478912
Br J Cancer. 2015 Jun 30;113(1):76-82
pubmed: 26057452
Radiother Oncol. 2017 Feb;122(2):171-177
pubmed: 27528118
Clin Cancer Res. 2019 Mar 1;25(5):1505-1516
pubmed: 30171046
Radiat Oncol. 2018 Jul 3;13(1):123
pubmed: 29970111
Radiat Oncol. 2019 Feb 11;14(1):32
pubmed: 30744643
J Clin Oncol. 2003 Jan 1;21(1):92-8
pubmed: 12506176
BMC Cancer. 2014 Mar 14;14:187
pubmed: 24629046
J Clin Oncol. 2016 Apr 20;34(12):1300-8
pubmed: 26712222
Oncotarget. 2016 Aug 2;7(31):50781-50804
pubmed: 27434126
Lancet. 2019 Jan 5;393(10166):51-60
pubmed: 30449623
J Clin Oncol. 2014 Sep 20;32(27):2940-50
pubmed: 25154822
J Clin Oncol. 2005 Feb 20;23(6):1125-35
pubmed: 15718308
Ann Oncol. 2010 Oct;21 Suppl 7:vii167-72
pubmed: 20943610
Int J Lab Hematol. 2008 Jun;30(3):177-84
pubmed: 18479294
Sci Rep. 2018 Oct 1;8(1):14582
pubmed: 30275505